iBio, Inc. (NasdaqCM: IBIO)
Health Care · Biotechnology · US
$0.77
-12.02% today · -14.2% 1Y
iBio, Inc. (NasdaqCM: IBIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $49.28M and employs 23 people.
Over the last twelve months the share price has lost 14.2%, trading between 0.73 and 3.82.
Tweenvest scores iBio, Inc. across four factors: quality 38/100, value 36/100. Its strongest factor is quality.
IBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $49.28M
- Revenue (TTM)
- $100.00K
- P/E
- —
- EPS
- -0.32
- Dividend yield
- —
- Beta (5Y)
- 1.26
- 52-week high
- $3.82
- 52-week low
- $0.73
- Avg volume (3M)
- —
- Shares outstanding
- 64.31M
- Employees
- 23
- Next earnings
- —
About iBio, Inc.
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
- ISIN
- US4510337086
- Founded
- 2008
- Listed since
- Aug 19, 2008
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Naturalendo Tech Co., Ltd.KOSDAQ: A168330 | $50.32M | ₩2,125.00 | -11.09% |
| Kidswell Bio CorporationTSE: 4584 | $50.31M | ¥157.00 | -1.88% |
| Arecor Therapeutics plcAIM: AREC | $49.86M | £0.83 | +13.79% |
| Alterity Therapeutics LimitedASX: ATH | $49.42M | AU$0.31 | -12.68% |
| Xspray Pharma AB (publ)OM: XSPRAY | $49.23M | Skr10.30 | -3.92% |
| Adicet Bio, Inc.NasdaqCM: ACET | $49.19M | $4.57 | -18.54% |
| PanGen Biotech Inc.KOSDAQ: A222110 | $49.11M | ₩4,845.00 | +3.75% |
| Amicogen, Inc.KOSDAQ: A092040 | $48.83M | ₩924.00 | -6.29% |
Figures last refreshed Oct 18, 2026.